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be used to evaluate coronary artery plaques. It allows for the simul-
taneous assessment of a left atrial appendage (LAA) thrombus, left
atrium (LA) thrombus and PVT [6]. I have reported several case re-
ports of PVT in elderly patients with chest pain using a 64-MDCT. Re-
cently, I reported 61% (35 patients) of 57 elderly patients with chest
pain had PVT, which indicates PVT is not uncommon [6]. However,
few other cases of PVT have been reported. Therefore, the existence
of PVT is not widely recognized. Although warfarin has been used
as the ﬁrst choice for patients with AF, dabigatran appears to be a
more useful current option. I have reported cases in which
dabigatran partially dissolved a PVT [6,7].Ischemic stroke is severe clinical problem, and preventing ischemic
stroke is an important clinical target. A left atrial thrombus can cause
an ischemic stroke [1]. In 2015, I reported that pulmonary vein throm-
bus (PVT) is a root cause of nearly all left atrial thrombi [2], suggesting
a link between PVT and ischemic stroke. I published a case report dem-
onstrating that an elderly patient with ischemic stroke had a PVT [3].
However, the relationship between PVT and the autonomic nervous
system (ANS) remains unclear.
Cerebralmicrovascular occlusion leads to chronic cerebral hypoperfu-
sion and consequent hypoxia. Itmayplay a direct role in the pathogenesis
of Alzheimer's disease or the development of dementia. However, cere-
bral microvascular occlusion is an underappreciated mechanism of
brain pathology. If prompt recanalization of the microvascular occlusion
fails, brain circuits can be disrupted and signiﬁcant functional deﬁcits
can occur [4].
In a previous report using mice, microemboli that occluded cerebral
microvesselswere extruded. After a complete recanalization, the emboli
translocated outside the vessel lumen within two to seven days [5].
When microvessels are occluded by microclots, recanalization should
also be performed in humans. However, the source of microclots is not
yet fully understood.
Pulmonary vein thrombus (PVT) is a life-threatening condition. PVT
has been reported to occur after lung cancer, pulmonary resection, lung
transplantation, and radiofrequency ablation for atrial ﬁbrillation (AF),
but the condition is believed to be rare.land Ltd. This is an open access articlA 64-slice multidetector computed tomography (64-MDCT) can
The coefﬁcient of variation of the R-wave to R-wave interval (CVRR) is
a parameter of heart rate variability (HRV) that is easily obtained using a
24-hour Holter electrocardiogram (ECG), which can be performed non-
invasively. CVRR is deﬁned as the standard deviation of all R–R intervals
divided by the mean of all R–R intervals, which is then multiplied by
100. Reduced CVRR is an index of sympathetic nerve predominance
when the parasympathetic nerve is in a withdrawal state. Reduced
CVRR has been reported to predict cardiovascular events, such as sudden
death andmyocardial infarction, in patients with coronary artery disease
and in apparently healthy subjects [8].
This case report presents a patient with PVT who had a decreased
CVRR value. This indicates that a PVT may occlude the microvessels of
the nervous system and aggravate the ANS.
The patient was an 82-year-oldmalewith hypertension and dyslipid-
emia. The patient presented with chest pain and was referred for a coro-
nary artery assessment. The patient's BMIwas 22.8 kg/m2. ECG showed a
complete right bundle branch blockwith no signiﬁcant ST-T changes. The
D-dimer level was less than 0.5 μg/ml (normal; b1.0 μg/ml); the activity
of protein Swas 85% (normal; 60–150%), and the activity of protein Cwas
107% (normal; 64–146%). The patient was not treated with anticoagu-
lants. The chest roentgenogram showed no lung cancer. The patient
had no symptoms of cough, fever, cerebral infarction, or cancer. The vol-
ume of the LAwas 22.1 ml. The CVRR valuewas decreased to 7 (normal
range; 18 to 25 for his age), indicating ANS dysfunction. A 64-MDCT
scan was performed and showed no coronary artery plaques. However
the scan showed a thrombus in the right lower pulmonary vein in
the axial (Fig. 1A), coronal (Fig. 1B) and sagittal planes (Fig. 1C). After
three months of dabigatran therapy, the images became vague, ﬁne,
and clear (Fig. 2A to 2C), suggesting that the thrombus had mostly
dissolved and that the contrast enhancements had penetrated the
thrombus.e under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Fig. 1. A: Axial images showing a thrombus in the right lower pulmonary vein with no contrast enhancement (arrow). B: Coronial images showing a thrombus in the right lower pulmo-
nary vein with no contrast enhancement (arrow). C: Sagittal images showing a thrombus in the right lower pulmonary vein attached to the inferior wall with no contrast enhancement
(arrow). AAo: ascending aorta, DAo: descending aorta, LA: left atrium, LV: left ventricle, RLPV: right lower pulmonary vein.
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with PVT. Dabigatran appeared to partially dissolve the thrombus.
However, the images demonstrate remnants of the thrombus, which
may be a ﬁbrin network, after three months on the dabigatran therapy
(Fig. 2A to 2C).
A PVT can release microclots that affect the ANS by occluding ner-
vous system microvessels. Presently, there are some candidates for
PVT indicators, such as age and total bilirubin [6]. A decreased CVRR
may be used as a new indicator. A decreased CVRR is associated with
sudden death and cardiac events [8], and it may be caused by occlusions
of the cerebral or coronary arteries. These occlusions may be caused by
clots that are released by a PVT.
ANS function and viability depend on suitable arterial blood ﬂow
through microvessels for adequate oxygen and glucose supply.
Mechanisms likely evolved to ensure microvessel patency [5].
Microvessels are believed to be prone to occlusion by microemboli.
Microclots released from a PVT can become microemboli. If revascu-
larization of the occluded microvessels fails, then the occluded
microvessels can cause hypoxia and undernourishment in the tissue
and, thus, injure normal cell functions. Hypoxia and undernourish-
ment result in a decrease of the production of ATP which causes
mitochondria dysfunction. PVT is a potentially life-threatening con-
dition that is often underdiagnosed and under-recognized. Basic
suspicion is necessary to diagnose a PVT. Although I have published
several cases of PVT in elderly patients with chest pain [2,3,6,7]which suggests that PVT is not uncommon, little is presently
known about the condition.
Hypoxia and undernourishment can activate transcription factors,
including hypoxia inducible factors (HIFs), nuclear respiratory factor-1
(NRF-1), and metal response transcription factor-1 (MTF-1). HIFs acti-
vate several target genes and may activate functional non-coding
RNAs. Glycolytic genes are well-known targets of HIFs. Glycolytic func-
tional non-coding RNAs may also be targets. To maintain ATP produc-
tion, these genetic factors change the energy production of the cell
from oxidative phosphorylation to glycolysis. This energetic change re-
sults in a decrease in reactive oxygen species (ROS) production from the
electron transport chain. ROS is a major source of metabolic damage to
cells [9], which can disrupt ANS function.
I previously reported that PVT was dissolved by warfarin [3] and
dabigatran [6,7]. In this case, the thrombus was partially dissolved by
dabigatran, and some arterial blood ﬂow was restored. Warfarin and
new anticoagulants, such as dabigatran, may prevent ischemic stroke
in AF patients by dissolving the PVT and the connected left atrial throm-
bus. Further studies are needed to conﬁrm this beneﬁt.
Anticoagulants, such as warfarin or dabigatran, may partially dissolve
a thrombus that is occluding ANS microvessels. Oxygen and glucose can
then be restored to the brain. However, the brain cannot necessarily re-
store normal ANS function. A long-lasting hypoperfusion may change
the quality of the ANS cells because of mitochondrial dysfunctions and
the activation of HIFs, NRF-1, and MTF-1, which may affect cerebral
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Fig. 2.A: Axial images vaguely showing an apparently small thrombus in the right lower pulmonary veinwith no contrast enhancement (arrow). B: Coronial images showing a decreased
thrombus in the right lower pulmonary veinwith no contrast enhancement (arrow); the thrombus appears as a ﬁne needle. C: Sagittal images showing a small thrombus on the bottom of
the right lower pulmonary vein (arrow). AAo: ascending aorta, DAo: descending aorta, LA: left atrium, RLPV: right lower pulmonary vein.
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in ANS dysfunction, dementia, and Alzheimer's disease.
The mechanism of PVT formation is not fully understood. Under-
standing the mechanism is important to prevent the injurious effects
of PVT onmany organs. Blood stasis and hypercoagulability are two cru-
cial predisposing factors for the development of venous thrombosis.
Physically demanding activities increase cardiac output and subsequent
cardiac input. Daily body activity may inhibit PVT production by in-
creasing cardiac input through thepulmonary veins, thereby preventing
blood stasis in the pulmonary veins. Recently, Kim and their colleagues
reported that TSC-1 inhibited chronic artery thrombus formation with
no effects on acute thrombus formation [10]. The pulmonary vein in-
cludes arterial blood, and TSC-1 may be associated with pulmonary
vein thrombus formation. More studies are needed to clarify this rela-
tionship. Understanding this relationship may lead to the development
of new medicines for ANS dysfunction, dementia and Alzheimer's
disease.
In brief, for the ﬁrst time, I reported on a patient with PVT and a de-
creased CVRR, indicating that a PVT aggravates the ANS. A decreased
CVRR may be an indicator of PVT. Microclots released from a PVT may
be a source of microemboli that occlude microvessels in all organs, in-
cluding ANS microvessels. In occluded microvessels, hypoxia and low
glucose levels can occur, which can injure normal cell function that
lead to not only ANSdysfunction but also dementia andAlzheimer's dis-
ease. Warfarin and dabigatran dissolved the PVT, indicating that theycan inhibit ANS dysfunction by decreasing the release of microclots. A
64-MDCT scan is useful to evaluate a PVT and the effects of warfarin
and dabigatran.
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